FTC v. Actavis - Where do Hatch-Waxman settlements go from here?
- 9.19.2013 | -
-
Boston Bar Association
16 Beacon Street
Boston, MA 02108
On June 17, 2013, the Supreme Court decided Federal Trade Commission v. Actavis, Inc., which resolved a circuit split over the appropriate antitrust standard to apply when evaluating "reverse payment" Hatch-Waxman patent litigation settlements. This decision has significant consequences for settlements in branded vs. generic abbreviated new drug application (ANDA) litigation in the pharmaceutical industry.
WilmerHale Partner Mark Ford is a featured speaker at this Boston Bar Association event, and will be presenting an antitrust analysis of reverse payment settlements in Hatch-Waxman cases.
